- Home
- GNE vs MREO Comparison
GNE vs MREO Comparison
Compare GNE & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNE
- MREO
- Stock Information
- Founded
- GNE 2011
- MREO 2015
- Country
- GNE United States
- MREO United Kingdom
- Employees
- GNE N/A
- MREO N/A
- Industry
- GNE Power Generation
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- GNE Utilities
- MREO Health Care
- Exchange
- GNE Nasdaq
- MREO Nasdaq
- Market Cap
- GNE 421.6M
- MREO 482.5M
- IPO Year
- GNE N/A
- MREO N/A
- Fundamental
- Price
- GNE $14.07
- MREO $2.85
- Analyst Decision
- GNE
- MREO Strong Buy
- Analyst Count
- GNE 0
- MREO 6
- Target Price
- GNE N/A
- MREO $7.83
- AVG Volume (30 Days)
- GNE 53.5K
- MREO 882.2K
- Earning Date
- GNE 03-10-2025
- MREO 03-26-2025
- Dividend Yield
- GNE 2.13%
- MREO N/A
- EPS Growth
- GNE N/A
- MREO N/A
- EPS
- GNE 0.12
- MREO N/A
- Revenue
- GNE $427,221,000.00
- MREO $1,000,000.00
- Revenue This Year
- GNE N/A
- MREO N/A
- Revenue Next Year
- GNE N/A
- MREO N/A
- P/E Ratio
- GNE $117.15
- MREO N/A
- Revenue Growth
- GNE 5.44
- MREO N/A
- 52 Week Low
- GNE $13.92
- MREO $2.53
- 52 Week High
- GNE $19.64
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- GNE 40.98
- MREO 38.17
- Support Level
- GNE $14.04
- MREO $2.82
- Resistance Level
- GNE $14.41
- MREO $2.99
- Average True Range (ATR)
- GNE 0.29
- MREO 0.13
- MACD
- GNE 0.01
- MREO 0.01
- Stochastic Oscillator
- GNE 15.46
- MREO 14.74
About GNE Genie Energy Ltd. Class B Stock
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).